Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass.

Br J Anaesth

Department of Anaesthesiology and Critical Care Medicine, OLV-Ziekenhuis, Aalst, Belgium.

Published: May 2000

We investigated the influence of mild hypothermic cardiopulmonary bypass (CPB) on the dose requirements of cisatracurium or rocuronium used as a continuous infusion. We studied eight patients given cisatracurium and nine given rocuronium. They were ASA class III and IV and scheduled for elective coronary artery bypass grafting. Neuromuscular transmission was monitored electromyographically. After recovery of T1/T0 to 10%, a cisatracurium infusion or a rocuronium infusion was started at a rate of 1.5 or 10 micrograms kg-1 min-1, respectively, and adjusted to maintain T1/T0 at 15%. Infusion rate and duration were recorded before, during and after CPB in each patient and the mean infusion rates were calculated. One-way ANOVA showed a statistically significant difference between the cisatracurium infusion rates before, during and after CPB: A T1/T0 of 15% could be achieved with a mean infusion rate of 1.1, 0.75 and 0.98 micrograms kg-1 min-1 before, during and after CPB, respectively. There was no significant difference between the rocuronium infusion rates before, during and after CPB. The mean rocuronium infusion rate required to maintain T1/T0 at 15% throughout the procedure was 4.1 micrograms kg-1 min-1. Cisatracurium infusion rates should be halved during CPB. Even after CPB, requirements are reduced. The same tendency occurs with rocuronium, but the changes in infusion rate were not statistically significant.

Download full-text PDF

Source
http://dx.doi.org/10.1093/bja/84.5.587DOI Listing

Publication Analysis

Top Keywords

infusion rate
16
infusion rates
16
cisatracurium rocuronium
12
cisatracurium infusion
12
rocuronium infusion
12
micrograms kg-1
12
kg-1 min-1
12
t1/t0 15%
12
infusion
11
dose requirements
8

Similar Publications

Background: Infantile epileptic spasm syndrome (ISS) is an age-dependent epileptic condition typically emerging within the first year of life, and adrenocorticotropic hormone (ACTH) has been established as a first-line therapeutic drug for the ISS since 1958. However, there is a notable variation in ACTH dosage practices worldwide, with intramuscular injection being common in some countries and intravenous drip preferred in others, including China. This study aimed to identify a preferable administration modality for ACTH-based utilization in treating ISS.

View Article and Find Full Text PDF

Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel ( = 162) versus cilta-cel ( = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS).

View Article and Find Full Text PDF

Data on the impact of ethnic and socioeconomic factors on Chimeric antigen receptor (CAR) T-cell therapy (access and outcomes are limited, but key to understand whether results from the registration trials are generalizable to real-world patient populations. Here, we analysed ethnicity, socioeconomic deprivation and referral patterns in a cohort of 314 large B-cell lymphoma patients approved for third-line CD19 CAR-T across three large UK CAR-T centres. Patients from deprived areas had a lower infusion rate compared to low deprivation areas (73% vs.

View Article and Find Full Text PDF

Background: Endotoxaemia is a common condition in equids, frequently accompanied by alterations in haemostasis. Non-steroidal anti-inflammatory drugs, such as meloxicam, have been proven to alleviate some signs of endotoxaemia in donkeys. Neither the haemostatic response to induced endotoxaemia nor the effect of meloxicam in this regard have been described in donkeys.

View Article and Find Full Text PDF

Background: A. muciniphila (AKK) has attracted extensive research interest as a potential next-generation probiotics, but its role in intestinal pathology is remains unclear. Herein, this study was conducted to investigate the effects of A.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!